Clinical features, management and outcomes of peritoneal dialysis patients during Delta and Omicron waves of COVID-19 infections
Authors:
Open Access
- 23 February 2023
- journal article
- research article
- Published by Springer Nature in International Urology and Nephrology
- Vol. 55 (8) , 2075-2081
Abstract
Introduction There were discrete outbreaks of SARS-CoV-2 infection in 2021 (Delta wave) and 2022 (Omicron wave) in Singapore, which affected patients receiving peritoneal dialysis (PD). Methods This study included all PD patients with COVID-19 infection from a single center between October 2021 and March 2022. The clinical presentation, management and outcomes of patients during the Delta and Omicron outbreaks were compared. Results A total of 44 PD patients developed SARS-CoV-2 infection (23 during the Delta wave and 21 during the Omicron wave): median age 66 (60.5–68.5) years, male (63.6%), Chinese ethnic (77.3%), diabetes mellitus (56.8%), and cardiovascular disease (45.5%). Approximately, 93.2% received two doses of the mRNA COVID-19 vaccine. Cough (81.8%) and fever (54.5%) were common presenting symptoms. Chest radiography showed ground glass opacity in 23.5% of patients, consolidation in 55.6%, and bilateral lung involvement in 33.3%. Eleven patients (25.6%) received antiviral therapy (Remdesivir), 7 (16.3%) received steroid, and 4 (9.3%) received monoclonal antibodies. Patients infected during the Delta wave were more likely to be hospitalized (73.9 vs 14.3%; p < 0.001) and receive antiviral therapy (39.1 vs 10.0%; p = 0.03) than those during the Omicron wave. The overall mortality rate was 11.4%, with significantly higher mortality during the Delta wave than during the Omicron wave (21.7 vs 0%; p = 0.03). Conclusions The mortality rate was high among infected PD patients during Delta wave of COVID-19 infection. However, during the Omicron wave, most infected patients were treated in the community with favorable outcomes.Keywords
This publication has 21 references indexed in Scilit:
- Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving hemodialysis: a call to armsKidney International, 2021
- Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patientsKidney International, 2021
- Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being wonKidney International, 2021
- Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients—a prospective cohort studyNephrology Dialysis Transplantation, 2021
- Strategies for Management of Peritoneal Dialysis Patients in Singapore during COVID-19 PandemicAnnals of the Academy of Medicine, Singapore, 2020
- A Longitudinal, 3-Month Serologic Assessment of SARS-CoV-2 Infections in a Belgian Hemodialysis FacilityClinical Journal of the American Society of Nephrology, 2020
- COVID-19 in Hospitalized Patients on Chronic Peritoneal Dialysis: A Case SeriesAmerican Journal of Nephrology, 2020
- Presentation and Outcomes of Patients with ESKD and COVID-19Journal of the American Society of Nephrology, 2020
- OUP accepted manuscriptClinical Kidney Journal, 2020
- Factors affecting responsiveness to hepatitis B immunization in dialysis patientsInternational Urology and Nephrology, 2017